Translational research: The changing landscape of drug discovery

Drug Discovery Today

Volumn 18, Issue 9-10, 2013, Pages 487-494

  Fishburn, C Simone ^a  

^a EXPONENT INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; DRUG DEVELOPMENT; DRUG INDUSTRY; HOSPITAL; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; REVIEW; TRANSLATIONAL RESEARCH; UNIVERSITY;

COOPERATIVE BEHAVIOR; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNIVERSITIES;

EID: 84876944176     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.12.002     Document Type: Review

References (40)

1. D. Butler Translational research: crossing the valley of death Nature 453 2008 840 842
2. P. Cuatrecasas Drug discovery in jeopardy J. Clin. Invest. 116 2006 2837 2842
3. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
4. F. Pammolli The productivity crisis in pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 428 438
5. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
6. A. Mullard 2011 FDA drug approvals Nat. Rev. Drug Discov. 11 2012 91 94
7. America, P.R.a.M.o. (2011) Pharmaceutical Industry Profile 2011. (PhRMA, ed.), PhRMA.
8. D. Cressey Traditional drug-discovery model ripe for reform Nature 471 2011 17 18
9. A. Maxmen Translational research: the American way Nature 478 2011 S16 S18
10. Y.L. Bennani Drug discovery in the next decade: innovation needed ASAP Drug Discov. Today 16 2011 779 792
11. A.L. Stinchcomb The role of entrepreneurial activities in academic pharmaceutical science research J. Pharm. Sci. 99 2010 2532 2537
12. R. Kneller The importance of new companies for drug discovery: origins of a decade of new drugs Nat. Rev. Drug Discov. 9 2010 867 882
13. A.J. Stevens The role of public-sector research in the discovery of drugs and vaccines N. Engl. J. Med. 364 2011 535 541
14. I. Sanchez-Serrano Success in translational research: lessons from the development of bortezomib Nat. Rev. Drug Discov. 5 2006 107 114
15. M. Wadman NIH encourages translational collaboration with industry Nat. Rev. Drug Discov. 9 2010 255 256
16. A.F. Cohen Developing drug prototypes: pharmacology replaces safety and tolerability? Nat. Rev. Drug Discov. 9 2010 856 865
17. G. Fitzgerald Drug development needs a new brand of science Nature 468 2010 869
18. E.A. Zerhouni US biomedical research: basic, translational, and clinical sciences JAMA 294 2005 1352 1358
19. M. Wadman Francis Collins: one year at the helm Nature 466 2010 808 810
20. K. Mullane, and M. Williams Translational semantics and infrastructure: another search for the emperor's new clothes? Drug Discov. Today 17 2012 459 468
21. S.H. Woolf The meaning of translational research and why it matters JAMA 299 2008 211 213
22. M.J. Khoury The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet. Med. 9 2007 665 674
23. S.M. Stahl Psychiatric stress testing: novel strategy for translational psychopharmacology Neuropsychopharmacology 35 2010 1413 1414
24. I.N. Sarkar Translational bioinformatics: linking knowledge across biological and clinical realms J. Am. Med. Inform. Assoc. 18 2011 354 357
25. D.Z. Wetmore, and C.C. Garner Emerging pharmacotherapies for neurodevelopmental disorders J. Dev. Behav. Pediatr. 31 2010 564 581
26. H. Ledford Translational research: the full cycle Nature 453 2008 843 845
27. S. Frye US academic drug discovery Nat. Rev. Drug Discov. 10 2011 409 410
28. W.E. Reddick Voxel-based analysis of T2 hyperintensities in white matter during treatment of childhood leukemia AJNR Am. J. Neuroradiol. 30 2009 1947 1954
29. W.E. Reddick Atypical white matter volume development in children following craniospinal irradiation Neuro-Oncol. 7 2005 12 19
30. M. Ratner Pfizer reaches out to academia-again Nat. Biotechnol. 29 2011 3 4
31. G. Sinha Pharma bankrolls academic institutes Nat. Biotechnol. 30 2012 474
32. M. Goldman Public-private partnerships need honest brokering Nat. Med. 18 2012 341
33. J. Kling Academia and the company coin Nat. Biotechnol. 27 2009 411 414
34. Leuty, R. (2012) QB3 Powers New Wave of Bio Startups. In San Francisco Business Times, Mary Huss.
35. S. Finkbeiner Bridging the Valley of Death of therapeutics for neurodegeneration Nat. Med. 16 2010 1227 1232
36. M. May Stanford program gives discoveries a shot at commercialization Nat. Med. 17 2011 1326 1327
37. R. Lalkaka Technology business incubators to help build an innovation-based economy J. Change Manage. 3 2002 167 176
38. B. Huggett Public biotech 2010-the numbers Nat. Biotechnol. 29 2011 585 591
39. Bement Jr, A.L. and Diaz, A.P. (2011) U.S. Public Research Universities. A Historical Perspective. In National Innovation Summit.
40. J. Hodgson Private biotech 2004-the numbers Nat. Biotechnol. 24 2006 635 641